blog navigation

blog posts

  • New lymphoma treatment shows promise in dogs

    After promising trials in mice, the researchers tested their compound, called S-PAC-1, on dogs. The drug arrested tumor growth in three of six dogs with lymphoma, and induced partial remission of tumors in a fourth, with minimal side effects. This dog, a Walker Tree Hound named Hoover, is a healthy research dog used to help determine the best dosing strategy for S-PAC-1. (Veterinary clinical medicine professor Tim Fan adopted Hoover at the completion of the study.)

    After promising trials in mice, the researchers tested their compound, called S-PAC-1, on dogs. The drug arrested tumor growth in three of six dogs with lymphoma, and induced partial remission of tumors in a fourth, with minimal side effects. This dog, a Walker Tree Hound named Hoover, is a healthy research dog used to help determine the best dosing strategy for S-PAC-1. (Veterinary clinical medicine professor Tim Fan adopted Hoover at the completion of the study.)

    Photo by L. Brian Stauffer

    Images

blog posts

  • Editor's note: To contact Paul Hergenrother, call 217-333-0363; e-mail hergenro@illinois.edu.
    To reach Tim Fan, call 217-333-5375; e-mail t-fan@illinois.edu. The paper, “Discovery and Canine Preclinical Assessment of a Nontoxic Procaspase-3-Activating Compound,” is available from the U. of I. News BureauEditor's note: To contact Paul Hergenrother, call 217-333-0363; e-mail hergenro@illinois.edu.
    To reach Tim Fan, call 217-333-5375; e-mail t-fan@illinois.edu. The paper, “Discovery and Canine Preclinical Assessment of a Nontoxic Procaspase-3-Activating Compound,” is available from the U. of I. News Bureau